Nassim Sleimann

5PUBLICATIONS
83CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 30, 2026
Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

|Feb 03, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu

|Oct 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.

Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht

|May 06, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.

Hans Prenen, Sanjeev Deva, Bhumsuk Keam

|Apr 17, 2024
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.

Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg

Pageof 1

Frequent Collaborators

4 joint publications

Christophe Boetsch

4 joint publications

Volker Teichgräber

4 joint publications

Jehad Charo

4 joint publications

Stefan Evers